Fish oil alters tamoxifen-modulated expression of mRNAs that encode genes related to differentiation, proliferation, metastasis, and immune response in rat mammary tumors

Nutrition and Cancer

Volumn 64, Issue 7, 2012, Pages 991-999

  Bidinotto, Lucas Tadeu ^a   De Cicco, Ricardo López ^a   Vanegas, Johana Erika ^a   Santucci Pereira, Julia ^a   Heuvel, John Patrick Vanden ^b   Washington, Sharlene ^c   Aliaga, Cesar ^c   Xu, Haifang ^c   Russo, Irma H ^a   Manni, Andrea ^c   El Bayoumy, Karam ^c   Russo, Jose ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

^c PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORN OIL; FISH OIL; GAMMA SYNUCLEIN; MESSENGER RNA; METHYLNITROSOUREA; SERINE PROTEINASE INHIBITOR; SOMATOMEDIN B; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOGENESIS; BREAST TUMOR; CHEMOPROPHYLAXIS; CONTROLLED STUDY; FAT INTAKE; FEMALE; FOOD DRUG INTERACTION; GENE EXPRESSION; GENETIC ANALYSIS; METASTASIS; NONHUMAN; RAT; TREATMENT DURATION; TUMOR DIFFERENTIATION; TUMOR GROWTH; TUMOR IMMUNITY;

ANIMALS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CORN OIL; DIETARY FATS; FEMALE; FISH OILS; GENE EXPRESSION REGULATION, NEOPLASTIC; IMMUNITY; MAMMARY NEOPLASMS, EXPERIMENTAL; METHYLNITROSOUREA; POLYMERASE CHAIN REACTION; RATS; REPRODUCIBILITY OF RESULTS; RNA, MESSENGER; TAMOXIFEN; TRANSCRIPTOME;

EID: 84867833802     PISSN: 01635581     EISSN: 15327914     Source Type: Journal    
DOI: 10.1080/01635581.2012.712736     Document Type: Article

References (41)

1. American Cancer Society. 2010. Cancer Facts and Figures, Atlanta: American Cancer Society.
2. Cleator, S J, Ahamed, E, Coombes, R C, and, Palmieri, C. 2009. A 2009 update on the treatment of patients with hormone receptor-positive breast cancer. Clin Breast Cancer, 9 (Suppl 1): S6-S17.
3. Osborne, C K. 1998. Tamoxifen in the treatment of breast cancer. N Engl J Med, 339: 1609-1618.
4. Vogel, V G. 2010. Selective estrogen receptor modulators and aromatase inhibitors for breast cancer chemoprevention. Curr Drug Targets, 12: 1874-1887. Epub Dec 15
5. White, I N. 1999. The tamoxifen dilemma. Carcinogenesis, 20: 1153-1160.
6. Manni, A, Xu, H, Washington, S, Aliaga, C, Cooper, T. 2010. The impact of fish oil on the chemopreventive efficacy of tamoxifen against development of N-methyl-N-nitrosourea induced rat mammary carcinogenesis. Cancer Prev Res (Phila), 3: 322-330.
7. Shao, Y, Pardini, L, and, Pardini, R S. 1995. Dietary menhaden oil enhances mitomycin C antitumor activity toward human mammary carcinoma MX-1. Lipids, 30: 1035-1045.
8. Hardman, W E, Avula, C P, Fernandes, G, and, Cameron, I L. 2001. Three percent dietary fish oil concentrate increased efficacy of doxorubicin against MDA-MB 231 breast cancer xenografts. Clin Cancer Res, 7: 2041-2049.
9. Calviello, G. 2010. Dietary omega-3 polyunsaturated fatty acids and cancer, Dordrecht, Germany and New York: Springer.
10. Smyth, G K. 2005. Limma: linear models for microarray data. In Bioinformatics and Computational Biology Solutions using R and Bioconductor, Edited by: Gentleman, R, Carey, V, Dudoit, S, Irizarry, R and Huber, W. 397-420. New York: Springer.
11. Ashburner, M, Ball, C A, Blake, J A, Botstein, D, Butler, H. 2000. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet, 25: 25-29.
12. Gopinathan, L, Hannon, D B, Smith, R W III, Peters, J M, and, Vanden Heuvel, J P. 2008. Regulation of peroxisome proliferator-activated receptors by e6-associated protein. PPAR Res, 2008: 1-8.
13. Banerjee, S, Dhar, G, Haque, I, Kambhampati, S, Mehta, S. 2008. CCN5/WISP-2 expression in breast adenocarcinoma is associated with less frequent progression of the disease and suppresses the invasive phenotypes of tumor cells. Cancer Res, 68: 7606-7612.
14. Dhar, G, Banerjee, S, Dhar, K, Tawfik, O, Mayo, M S. 2008. Gain of oncogenic function of p53 mutants induces invasive phenotypes in human breast cancer cells by silencing CCN5/WISP-2. Cancer Res, 68: 4580-4587.
15. Diez-Itza, I, Vizoso, F, Merino, A M, Sanchez, L M, Tolivia, J. 1994. Expression and prognostic significance of apolipoprotein D in breast cancer. Am J Pathol, 144: 310-320.
16. Stewart, L V, Song, K, Hsing, A Y, and, Danielpour, D. 2003. Regulation of trespin expression by modulators of cell growth, differentiation, and apoptosis in prostatic epithelial cells. ExpCell Res, 284: 303-315.
17. Ulger, C, Toruner, G A, Alkan, M, Mohammed, M, Damani, S. 2003. Comprehensive genome wide comparison of DNA and RNA level scan using microarray technology for identification of candidate cancer-related genes in the HL-60 cell line. Cancer Genet Cytogenet, 147: 28-35.
18. Lottin, S, Adriaenssens, E, Dupressoir, T, Berteaux, N, Montpellier, C. 2002. Overexpression of an ectopic H19 gene enhances the tumorigenic properties of breast cancer cells. Carcinogenesis, 23: 1885-1895.
19. Adriaenssens, E, Lottin, S, Dugimont, T, Fauquette, W, Coll, J. 1999. Steroid hormones modulate H19 gene expression in both mammary gland and uterus. Oncogene, 18: 4460-4473.
20. Rasmussen, A A, and, Cullen, K J. 1998. Paracrine/autocrine regulation of breast cancer by the insulin like growth factors. Breast Cancer Res Treat, 47: 219-233.
21. Christofori, G, Naik, P, and, Hanahan, D. 1994. A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis. Nature, 369: 414-418.
22. Manni, A, Badger, B, Wei, L, Zaenglein, A, Grove, R. 1994. Hormonal regulation of insulin like growth factor II and insulin-like growth factor binding protein expression by breast cancer cells in vivo: evidence for stromal epithelial interactions. Cancer Res, 54: 2934-2942.
23. Brunner, N, Yee, D, Kern, F G, Spang-Thomsen, M, Lippman, M E. 1993. Effect of endocrinetherapy on growth of T61 human breast cancer xenografts is directly correlated to a specific down-regulation of insulin-like growth factor II (IGF-II). Eur J Cancer, 29A: 562-569.
24. Guo, J, Shou, C, Meng, L, Jiang, B, Dong, B. 2007. Neuronal protein synuclein gamma predicts poor clinical outcome in breast cancer. Int J Cancer, 121: 1296-1305.
25. Jiang, Y, Liu, Y E, Lu, A, Gupta, A, Goldberg, I D. 2003. Stimulation of estrogen receptor signaling by gamma synuclein. Cancer Res, 63: 3899-3903.
26. Jia, T, Liu, Y E, Liu, J, and, Shi, Y E. 1999. Stimulation of breast cancer invasion and metastasis by synuclein gamma. Cancer Res, 59: 742-747.
27. Ning, S, Pagano, J S, and, Barber, G N. 2011. IRF7: Activation, regulation, modification and function. Genes Immun, 12: 399-414.
28. Romieu-Mourez, R, Solis, M, Nardin, A, Goubau, D, Baron-Bodo, V. 2006. Distinct roles for IFN regulatory factor (IRF)-3 and IRF-7 in the activation of antitumor properties of human macrophages. Cancer Res, 66: 10576-10585.
29. Andrews, H N, Mullan, P B, McWilliams, S, Sebelova, S, Quinn, J E. 2002. BRCA1 regulates the interferon gamma-mediated apoptotic response. J Biol Chem, 277: 26225-26232.
30. Berquin, I M, Edwards, I J, and, Chen, Y Q. 2008. Multi-targeted therapy of cancer by omega-3 fatty acids. Cancer Lett, 269: 363-377.
31. Calder, P C, Yaqoob, P, Thies, F, Wallace, F A, and, Miles, E A. 2002. Fatty acids and lymphocyte functions. Br J Nutr, 87 (Suppl 1): S31-S48.
32. Dobrzanski, M J, Reome, J B, and, Dutton, R W. 2000. Type 1 and type 2 CD8+ effector T cell subpopulations promote long-term tumor immunity and protection to progressively growing tumor. J Immunol, 164: 916-925.
33. Sheu, B C, Lin, R H, Lien, H C, Ho, H N, Hsu, S M. 2001. Predominant Th2/Tc2 polarity of tumor-infiltrating lymphocytes in human cervical cancer. J Immunol, 167: 2972-2978.
34. Dobrzanski, M J, Reome, J B, Hylind, J C, and, Rewers-Felkins, K A. 2006. CD8-mediated type 1antitumor responses selectively modulate endogenous differentiated and nondifferentiated T cell localization, activation, and function in progressive breast cancer. J Immunol, 177: 8191-8201.
35. Hegyesi, H, Colombo, L, Pallinger, E, Toth, S, Boer, K. 2007. Impact of systemic histamine deficiency on the crosstalk between mammary adenocarcinoma and T cells. J Pharmacol Sci, 105: 66-73.
36. Joshi, N, Johnson, L L, Wei, W Q, Abnet, C C, Dong, Z W. 2006. Gene expression differences in normal esophageal mucosa associated with regression and progression of mild and moderate squamous dysplasia in a high-risk Chinese population. Cancer Res, 66: 6851-6860.
37. Kraft, S, and, Kinet, J P. 2007. New developments in FcepsilonRI regulation, function and inhibition. Nat Rev Immunol, 7: 365-378.
38. Medina, V, Croci, M, Crescenti, E, Mohamad, N, Sanchez-Jimenez, F. 2008. The role of histamine in human mammary carcinogenesis: H3 and H4 receptors as potential therapeutic targets for breast cancer treatment. Cancer Biol Ther, 7: 28-35.
39. Cheng, W L, Wang, C S, Huang, Y H, Liang, Y, Lin, P Y. 2008. Overexpression of a secretory leukocyte protease inhibitor in human gastric cancer. Int J Cancer, 123: 1787-1796.
40. Devoogdt, N, Rasool, N, Hoskins, E, Simpkins, F, Tchabo, N. 2009. Overexpression of protease inhibitor-dead secretory leukocyte protease inhibitor causes more aggressive ovarian cancer in vitro and in vivo. Cancer Sci, 100: 434-440.
41. Devoogdt, N, Hassanzadeh Ghassabeh, G, Zhang, J, Brys, L, De Baetselier, P. 2003. Secretory leukocyte protease inhibitor promotes the tumorigenic and metastatic potential of cancer cells. Proc Natl Acad Sci U S A, 100: 5778-5782.